AI Summit 2022
The 2022 AI Summit attracted more than 95 participants who journeyed together through a wide range of topics, built bridges to different ideas and concepts and came away with action items and plans to move AI in healthcare forward.
If you are looking for solutions to launch and advance AI capabilities, join us next year.
Check out the AI Global Initiative here | Sign up for the AI Summit Mailing list
2022 Speaker Highlights
Bakul Patel
Senior Director, Global Digital Health Strategy & Regulatory, Google
Toni Manzano
Co-founder and CSO, Aizon
Pat Baird
Regulatory Head of Global Software Standards,
Philips
Jesse M. Ehrenfeld
President-Elect, American Medical Association
Jeff Ballyns
Associate Director Regulatory Policy, BD
Sundar Selvatharasu
Chief Compliance Officer – GxP Operations, Sierra Labs
Ling Koh
Regulatory Affairs Manager, BD
Eric Henry
Senior Quality & Regulatory Compliance Advisor, FDA & Life Sciences Practice, King & Spalding
A look back at the 2022 Summit
The 2022 summit was held in person in Columbus, Ohio — where we had a behind-the-scenes look into how Artificial Intelligence (AI) is being used in pharma, biopharma, and medical devices!
Featured Topics
1
QMS Case Study – A Real-World Experience Aligning AI/ML Activities with a Compliant QMS
2
Current AI Global Regulatory and Standards Landscape
3
Lessons Learned: Bringing an AI-Enabled Device to Market Through a Pandemic
4
Lessons Learned and Pitfalls When Deploying AI in GxP Environments
5
How AI Can Be Used in 3D Printing & Smart Manufacturing
6
Learn What the Industry-Led AI Working Teams Have Been Up To
Who attended the AI Summit?
Quality, regulatory, operations, and R&D professionals in the healthcare space
Healthcare professionals who are using or building AI solutions
Clinical trial managers
Biopharma and biotech professionals
Healthcare executives
Consultants and service providers to the life science industries
Data scientists and AI experts
This meeting is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award FAIN R13FD007707 totaling $50,000 funded by FDA/HHS and $76,000 amount and funded by non-government source(s). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.
